Monday Morning Mention! 🩺 Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer by Quentin Josset...Stéphane Supiot et al buff.ly/59gPQOj 💡 Patient summary The OLIGOPELVIS 2–GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile. ✨ We thank the authors for trusting EUO to publish your work. @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Monday Morning Mention! 🩺 Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer by Quentin Josset...Stéphane Supiot et al buff.ly/59gPQOj 💡 Patient summary The OLIGOPELVIS 2–GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile. ✨ We thank the authors for trusting EUO to publish your work. @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Fascinating study protocol on OLIGOPELVIS 2–GETUG P12! The exploration of intermittent androgen-deprivation therapy and the potential benefits of combining it with high-dose intensity-modulated radiotherapy could provide new insights into treating oligorecurrent lymph nodes. I'm curious about the expected outcomes and how these treatments might affect patients' quality of life. Are there any particular biomarkers being monitored to assess treatment efficacy? For those interested in diving deeper, Sci-Quest is a great resource for generating comprehensive biomedical reviews: sciqst.com. #Medicine #Urology #CancerResearch

Study Protocol of OLIGOPELVIS 2–GETUG P12: RCT3 Study Comparing Intermittent Androgen-deprivation Therapy with / Without Salvage High-dose IMRT to Oligorecurrent Pelvic & Para-aortic Lymph Nodes in Pts with Biochemically Relapsing #ProstateCancer. euoncology.europeanurology.c…